Finance Watch: Venture Capital On Track For Another Record Year
$20.3bn Raised In H1 2021 Versus $27.2bn For All Of 2020
Private Company Edition: With $8.9bn raised in the second quarter, venture capital investment in biopharma companies reached its second highest quarterly total to date – behind only Q1 of this year. Also, Nimbus Therapeutics raised $105m and European drug developers get in on the VC action.
You may also be interested in...
The company sees its gene-editing technology, which it compares to a DNA “word processor,” as having potentially broad applicability.
Armed with €26m in fresh funds from investors that include partner Regeneron, ISA Pharma can now advance promising preclinical assets generated from its proprietary platform, containing a mix of synthetic antigenic peptides, its CEO tells Scrip.
Backed by investors such as Sofinnova, Polaris and Sanofi Ventures, Muna has assembled a strong team dedicated to developing small molecules to repair neuronal dysfunction and resolve neuroinflammation.